- Tytuł:
- Sclerotherapy of esophageal varices in severe hemophilia a patient and high titer inhibitor – case report
- Autorzy:
-
Szczepanik, Andrzej
Dąbrwski, Wojciech
Szczepaniak, Anna
Pielaciński, Konrad
Jaśkowiak, Wojciech - Powiązania:
- https://bibliotekanauki.pl/articles/1394398.pdf
- Data publikacji:
- 2015
- Wydawca:
- Index Copernicus International
- Tematy:
-
hemophilia
inhibitor
esophageal varices
injection sclerotherapy
aPCC
rFVIIa - Opis:
- In cirrhotic hemophilia patients bleeding from esophageal varices is a serious clinical condition due to congenital deficiency of clotting factors VIII or IX, decreased prothrombin synthesis and hypersplenic thrombocytopenia. In hemophiliac with high-titer inhibitor bypassing therapy is required with activated prothrombin complex concentrates (aPCC) or recombinant activated coagulation factor VII (rFVIIa). Doses and duration treatment with these agents following endoscopic treatment of esophageal varices have not been yet established. Authors report the first case of a severe hemophilia A patient with high titer inhibitor (40 BU) treated with repeated injection sclerotherapy. The patient was admitted with symptoms of massive esophageal variceal hemorrhage ceased with emergency sclerotherapy. Bypassing therapy was administered with aPCC at initial dose of 72.5 U/kg and then with average daily dose of 162 U/kg through 5 days. To achieved a total eradication of esophageal varices the patient was then subjected to four elective sclerotherapy procedures. Two were covered by aPCC with daily dose of 120 U/kg and 145 U/kg for 4 and 3 days respectively and the following two procedures were covered by rFVIIa with the initial dose of 116 µg/kg and the next doses of 87 µg/kg administered every 3 hours in procedure day and every 4 hours on the next two days. During all procedures excellent hemostasis was achieved and no hemorrhagic or thromboembolic complications were observed. Bypassing regimen therapy with aPCC and rFVIIa we applied have been shown to be safe and effective in this patient subjected to sclerotherapy procedures.
- Źródło:
-
Polish Journal of Surgery; 2015, 87, 9; 464-468
0032-373X
2299-2847 - Pojawia się w:
- Polish Journal of Surgery
- Dostawca treści:
- Biblioteka Nauki
Artykuł